| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bfe86ae8785e873f909bdbdefcbbbe21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f873c586b280f965dd3090b8370d629 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2002-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a31f29fb502f6064a2ff6d6445992b25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_357e34534b88e84fdbd7c29154909110
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_398799df89769a32582b77137be9f813 |
| publicationDate |
2019-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SK-288719-B6 |
| titleOfInvention |
40-O- (2-hydroxyethyl) -rapamycin for use as the only active ingredient in the treatment of solid tumor |
| abstract |
40-O- (2-hydroxyethyl) -rapamycin (everolimus) is designed to be used as the only active ingredient in the treatment of pancreatic tumor. The antiproliferative and anti-angiogenic activity of 40-O- (2-hydroxyethyl) -rapamycin when used in combination with another active agent or alone is described. |
| priorityDate |
2002-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |